EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression

N Ezgi Wood iD, Anıl Cengiz, Ming Gao, Alexander V Ratushny, Ronny Straube

PLOS Computational Biology · 2025

DOI: 10.1371/journal.pcbi.1012839 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von N Ezgi Wood und 4 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Systems Pharmacology, Bristol Myers Squibb, Princeton, New Jersey, United States of America. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Models, Biological. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are gaining increasing traction in the treatment of oncological diseases; however, many clinical failures have also been observed. One key factor limiting ADC effectiveness is the heterogeneous expression of their target antigen. While the vast majority of ADCs in clinical development target antigens on cancer cells (cancer-targeting), they can also target antigens expressed on non-cancerous stromal cells in the tumor microenvironment (stroma-targeting). It remains unclear if ADCs targeting stromal cells can outperform cancer-targeting ADCs. Here, we present three related mathematical models to evaluate: (1) cancer-targeting ADCs with homogeneous target antigen expression, (2) cancer-targeting ADCs with heterogeneous target antigen expression, and (3) stroma-targeting ADCs. Our simulations suggest that cancer-targeting ADCs can achieve high efficacy when their target antigen is homogenously expressed. However, in cases of heterogeneous antigen expression, cancer-targeting ADCs may lead to an initial reduction in tumor size, followed by regrowth due to the elimination of antigen-positive cells and expansion of antigen-negative cells. This limitation could potentially be overcome by stroma-targeting ADCs, as antigen-positive stromal cells may continue to be recruited into the tumor by the oncogenic factors produced by the remaining cancer cells. Furthermore, we demonstrate that ADCs with more permeable payloads and less stable linkers may offer improved efficacy in the context of heterogeneous target expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsModels, BiologicalHumansTumor MicroenvironmentStromal CellsComputational BiologyAntigens, NeoplasmComputer SimulationAntineoplastic Agents

Substanzen

ImmunoconjugatesAntigens, NeoplasmAntineoplastic Agents

Autor:innen und Institutionen

  • Quantitative Systems Pharmacology, Bristol Myers Squibb, Princeton, New Jersey, United States of America.
  • Department of Mathematics, University of Utah, Salt Lake City, Utah, United States of America.
  • Quantitative Systems Pharmacology, Bristol Myers Squibb, Cambridge, Massachusetts, United States of America.
  • Quantitative Systems Pharmacology, Bristol Myers Squibb, Seattle, Washington, United States of America.

ORCID-Profile: N Ezgi Wood

Förderung

  • Bristol Myers Squibb
  • Bristol-Myers Squibb

Zitieren

APA

Wood, N. E., Cengiz, A., Gao, M., Ratushny, A. V., & Straube, R. (2025). Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1012839

Vancouver

Wood NE, Cengiz A, Gao M, Ratushny AV, Straube R. Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1012839

BibTeX
@article{Wood2025,
  author = {Wood, N Ezgi and Cengiz, Anıl and Gao, Ming and Ratushny, Alexander V and Straube, Ronny},
  title = {Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression},
  journal = {PLOS Computational Biology},
  year = {2025},
  doi = {10.1371/journal.pcbi.1012839}
}
Kostenlos starten →